share_log

東瑞製藥:有關合營公司的最新進展-Ebronucimab(PCSK9抑制劑)在中國治療高危或極高危高膽固醇血癥的IIb期臨床試驗提前完成患者入組

DAWNRAYS PHARMA: UPDATE ON JOINT VENTURE COMPANY-EARLY COMPLETION OF PATIENT ENROLLMENT IN PHASE IIB CLINICAL TRIAL FOR EBRONUCIMAB (PCSK9 INHIBITORS) FOR TREATING PATIENTS SUFFERING FROM HIGH- OR VERY HIGH-RISK HYPERCHOLESTEROLEMIA IN THE PRC

Dec 2, 2020 09:53
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more